Friday, April 17, 2026

Ferring Pharmaceuticals and Gallup Announce Landmark Global Public Attitudes Study on Fertility and Family-Building


 WASHINGTON - 

Ferring Global Fertility Monitor will gather data from a representative sample in 70 countries as a part of the Gallup World Poll

Consultation to gather expert opinion on high impact questions begins this year

The project aims to provide data and evidence to inform demography-related policymaking against a backdrop of total fertility rates dropping below replacement levels in many countries worldwide, with the U.S. reporting its lowest on record in the latest federal data released last week1

 


(BUSINESS WIRE)--Ferring Pharmaceuticals and Gallup today announced the Ferring Global Fertility Monitor, a global study on the factors influencing people’s fertility choices, at the 2026 Annual Convening of Semafor World Economy.


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415305082/en/


The Ferring Global Fertility Monitor is grounded in the recognition that declining global fertility rates are an increasingly significant public policy topic, with rates already well below replacement level in many countries. Rolled out as part of the Gallup World Poll, it will provide policymakers with robust, globally comparable data on the social, economic, cultural, and structural factors shaping fertility choices. By integrating these insights with people’s lived experiences, well-being, and aspirations, the Monitor supports more responsive, inclusive, and human-centred approaches to demographic change.


Jean-Frédéric Paulsen, Chairman of the Board of Directors and Chief Executive Officer of Ferring Pharmaceuticals, said: “As a company committed to supporting people on their fertility journey, we see the global debate on demographic change as one of the defining issues of our time. Around the world, questions about the future shape of populations are intensifying, yet the data needed to fully understand these shifts, and their implications, remains far too limited. This project has the potential to transform that landscape. By strengthening the global evidence base, we can deepen understanding of what is happening and why, helping governments, health systems and communities plan for a more sustainable future.”


Jon Clifton, Chief Executive Officer of Gallup, said: “We spend a lot of time debating falling fertility and birth rates, but surprisingly little time asking people why. This initiative changes that, using nationally representative data, collected consistently at a scale no one has attempted before across 70 countries."


In 2026, the Ferring Global Fertility Monitor will be developed through an expert consultation and research process designed to identify critical evidence gaps in how fertility decisions are understood across countries. A cognitively tested questionnaire will then enter the 2027 Gallup World Poll and run as a biannual tracker. When complete, the Monitor will represent one of the most comprehensive global data and evidence bases to date on how people think about parenthood, and what helps or hinders them from realising those aspirations.


The Gallup World Poll is the world’s largest private survey infrastructure, collecting annual data from around 140 countries. All data are nationally representative of the adult population and collected either via face-to-face or telephone interviewing. The World Poll collects data on a wide range of topics, all of which speak to how people’s lives are going.


About Gallup


Gallup delivers analytics and advice to help leaders and organisations solve their most pressing problems. Combining more than 85 years of experience and a global reach, Gallup knows more about the attitudes and behaviours of employees, customers, students and citizens than any other organisation in the world.


About Ferring Pharmaceuticals


Ferring Pharmaceuticals a privately owned, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,500 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.


Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram and YouTube.


Reference


1National Vital Statistics System; Births: Provisional Data for 2025; Report No.43; April 2026: Vital Statistics Rapid Release, Number 043 (April 2026) (Accessed April 2026)


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260415305082/en/



Permalink

https://www.aetoswire.com/en/news/1604202654368


Contacts

For more information, please contact


Ferring Pharmaceuticals

EU - Matthew Worrall, +44 7442 271 811, matthew.worrall@ferring.com

EU - Mary Knight, +44 7747 758 437, mary.knight@ferring.com

US - Lisa Perdomo, +1 (862) 341-9820, lisa.perdomo@ferring.com


Gallup

US - Riada Asimovic Akyol, +1 (202) 715-3095, Riada_akyol@gallup.com


 

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+™, Powered by Its Next-Generation TriHex Technology® Regenerative Platform


 ZUG, Switzerland - 

Regenerating Skin Nectar has long played a central role in the peri-procedural skin journey as part of Alastin’s dedicated procedure support portfolio, enhancing the body’s natural processes for removing damaged collagen and elastin while creating an optimal environment for new, healthy collagen and elastin production — visibly improving how the skin prepares for, responds to, and recovers from procedures.

With the addition of our proprietary Octapeptide‑45, Regenerating Skin Nectar with TriHex+™ introduces an advanced formulation that builds on the original Tri-Hex Technology® foundation, while further supporting the skin’s natural production of new collagen, elastin, and high‑molecular‑weight hyaluronic acid (HA).1

The new formulation also helps reinforce skin structure, restore skin barrier, and support long-term skin longevity.

This innovation underscores Galderma’s commitment to advancing peri-procedural skincare and empowering providers with science-based solutions designed to deliver exceptional aesthetic and procedural outcomes.

 


(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare.


As a pioneer in peri‑procedural skincare, Alastin helped establish the category with the original Regenerating Skin Nectar — one of the first products specifically developed to prepare the skin before cosmetic procedures, complement procedural outcomes, and visibly support a smoother, accelerated recovery.


For more than a decade, it has served as a foundational peri-procedural product used by aesthetic providers to improve skin readiness and enhance treatment response. Today, among physicians who offer the brand, Alastin is their preferred peri-procedural skincare choice, and it remains the only product in this category with published clinical data demonstrating the benefits of preconditioning the skin prior to a procedure.


The new and enhanced Regenerating Skin Nectar with TriHex+™ builds on this foundation with an advanced formulation designed to help visibly improve how the skin prepares for, responds to, and recovers from procedures. It complements a broad range of aesthetic and surgical procedures such as facelifts, microneedling, laser resurfacing, chemical peels, and radiofrequency ablation, among others.


Regenerating Skin Nectar with TriHex+™ is the second product to feature the next-generation TriHex+™ platform, following the successful launch of Restorative Skin Complex with TriHex+™. TriHex Technology® uniquely combines proprietary peptide components that help clear aged, damaged collagen and elastin while simultaneously supporting the production of new, healthy collagen and elastin — a dual mechanism that underpins its regenerative approach. TriHex+™ is the next evolution of this technology. The addition of proprietary Octapeptide‑45 advances this activity by supporting the skin’s natural production of high‑molecular‑weight HA, a critical component of skin structure and resilience, and working synergistically with TriHex Technology® to further enhance production of collagen, elastin, and HA. This reinforces the skin’s underlying structural integrity, including the dermal-epidermal junction (DEJ), and supports the skin’s response to procedural stress in ways that contribute to more consistent outcomes and long-term skin longevity.


 


“Galderma continues to deepen the understanding of extracellular matrix remodeling, which is now recognized as a key driver of skin aging and longevity. Our new TriHex+™ formulation represents the evolution of our regenerative platform, focusing on key proteins and membranes that influence how the skin responds to procedural stress at a structural level. This innovation reflects our continued commitment to developing science-driven solutions that not only aid in procedural outcomes, but also support a more resilient skin recovery.”


 


ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS


CHIEF SCIENTIFIC OFFICER, GALDERMA


HEAD, SKIN SCIENCE CENTER FOR INNOVATION


 


Peer-reviewed clinical studies support the use of Regenerating Skin Nectar with TriHex+™ as a foundational peri‑procedural product. In a randomized, double‑blind facelift pre‑conditioning study, 100% of patients showed visible improvements in key extracellular matrix (ECM) markers—including collagen, elastin, and high‑molecular‑weight HA—alongside reductions in solar elastosis and a stronger, more defined DEJ.2 The improvement in DEJ definition is clinically meaningful, as DEJ integrity helps skin better withstand mechanical and thermal stress during procedures.3,4 Additional evaluations demonstrated statistically significant improvements in skin barrier function as early as 30 minutes post-application, with continued improvement through day 14, alongside increased skin hydration observed from day 3.² Clinical grading and photography showed visibly improved healing responses, including reduced appearance of erythema (redness), edema (swelling), and crusting. Split‑face microneedling evaluations also demonstrated improved tolerability compared with exosome-based products.5 These findings reinforce the role of peri-procedural skincare in optimizing overall treatment outcomes.


The formulation is water-free, preservative-free, and bacteriostatic, allowing for use immediately following procedures. This enables early integration into post-procedure care when the skin is most vulnerable and requires products that will not irritate or disrupt healing.


 


“In my practice, patients are looking for treatments that deliver strong results while minimizing downtime. Alastin Regenerating Skin Nectar has helped support that balance by preparing the skin ahead of procedures, visibly improving how it responds during treatment, and promoting a more efficient recovery afterward. With TriHex+™, the clinical data demonstrates it supports advanced improvements in hydration, barrier function, and recovery response — factors I prioritize to help deliver more consistent, high-quality outcomes for my patients.”


 


NAZANIN SAEDI, MD


BOARD-CERTIFIED DERMATOLOGIST


DERMATOLOGY ASSOCIATES OF PLYMOUTH MEETING


 


Galderma will launch Regenerating Skin Nectar with TriHex+™ in the United States this month. For an extended initial period, the product will be available exclusively through authorized Alastin skincare providers and dispensed directly through medical aesthetic practices, including dermatology and plastic surgery offices, and medical spas. Galderma is working to expand availability to additional international markets where Alastin is present.


About Alastin

Alastin by Galderma is the leader in peri-procedural regenerative skincare, offering innovative, scientifically proven, and clinically tested products. The Alastin Skincare portfolio provides a comprehensive collection of cutting-edge formulas designed specifically for peri-procedural use, as well as daily skincare regimens, all powered by proprietary peptides and innovative, clinically meaningful, science-backed ingredients designed to amplify the skin’s own natural regenerative abilities. With more than 60 international dermatological publications and 20 patents granted, Alastin is one of the most clinically studied professional-grade skincare brands.


About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.


References


Widgerow AD, et al. J Drugs Dermatol. 2024 May 1;23(5):347-352.

Jalian HR, et al. J Cosmet Dermatol. 2025;24(12):e70556.

Roig-Rosello E, Rousselle P. Biomolecules. 2020;10:1607.

Fisher G, Rittié L. J Cell Commun Signal. 2018;12:401–411.

Widgerow AD, Ziegler ME, Shafiq F, et al. J Dermat Cosmetol. 2024;8(3):87–92.

 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260415545576/en/



Permalink

https://www.aetoswire.com/en/news/1604202654366


Contacts

For further information:


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50


Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com

+1 786 451 7740


Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87


Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12


Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43


Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Perma-Pipe International Holdings, Inc. Announces Record Fourth Quarter and Fiscal 2025 Results; Net Sales Increase 33% and Net Income Grows 89%

 THE WOODLANDS, Texas - Thursday, 16. April 2026



Net sales increased to $55.1 million for the quarter and $210.9 million for the full year, compared to $45.0 million and $158.4 million in the prior year periods, respectively

Income before income taxes increased to $6.4 million for the quarter and $27.5 million for the full year, compared to $5.3 million and $18.5 million in the prior year periods, respectively

GAAP diluted earnings per share increased to $0.60 for the quarter and $2.09 for the full year, compared to $0.22 and $1.12 in the prior year periods, respectively

Backlog stood at $121.6 million, reflecting strong conversion to revenue during the quarter

 


(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) today announced financial results for the fourth quarter and 2025 fiscal year ended January 31, 2026.


“For the three months ended January 31, 2026, net sales were $55.1 million, an increase of $10.1 million, or 22.4%, compared to $45.0 million in the same quarter of the prior year. Growth was driven by higher sales volumes in both the Middle East and North America. Gross profit was $17.3 million, up $2.1 million from $15.2 million last year, reflecting higher activity levels. Selling, general and administrative expenses increased slightly to $10.3 million from $9.7 million, primarily due to higher payroll costs, partially offset by lower bonus costs. The Company’s effective tax rate (“ETR”) was 12.3%, compared to 32.1% in the prior-year quarter, reflecting the impact of product mix across various tax jurisdictions. As a result, net income attributable to common stock was $4.9 million, an increase of $3.1 million, or 172.2%, compared to $1.8 million in the fourth quarter of fiscal 2024,” noted President and CEO Saleh Sagr.


“For the year ended January 31, 2026, net sales were $210.9 million, an increase of $52.5 million, or 33.1%, compared to $158.4 million in the prior year period. The increase was primarily attributable to higher sales volumes in both the Middle East and North America. Gross profit was $69.5 million, compared to $53.2 million in the prior year period, reflecting increased activity levels. Selling, general and administrative expenses were $40.1 million, up from $32.9 million, due to higher payroll and professional fees, including approximately $1.0 million related to Sarbanes-Oxley Section 404 compliance in connection with our transition from a non-accelerated filer to an accelerated filer. This also includes a one-time compensation charge of approximately $2.0 million related to the departure of the previous CEO. The Company’s effective tax rate was 24.9%, compared to 29.1% in the prior-year period. The change in the Company's effective tax rate reflects product mix across various tax jurisdictions and the Company’s overall reduction in its effective tax rate for the year was partially offset by the impact of a tax limitation related to the one-time charge associated with the prior CEO’s departure. Net income attributable to common stock was $17.0 million, an increase of $8.0 million, or 88.9%, compared to $9.0 million in fiscal 2024,” Mr. Sagr commented.


President and CEO Saleh Sagr added: “Our backlog stood at $121.6 million as of January 31, 2026. This reflects strong operational execution as we successfully accelerated the conversion of existing sales orders into realized revenue. Our backlog remains at historically strong levels. We continue to see meaningful multi-regional expansion, particularly across North America and the Middle East, reinforcing sustained global demand for our solutions.”


“Our fiscal 2025 results represent a landmark achievement for the Company. Total revenues of $210.9 million and net income attributable to common stockholders of $17.0 million mark our highest level of earnings in the Company’s modern operating history, driven not only by strong top-line growth but also by improved margins. This record performance was driven by broad-based strength across our global footprint, with significant growth contributions from the Middle East and North America. Our ability to scale across these diverse markets while maintaining disciplined margin performance has enabled us to convert top-line momentum into meaningful bottom-line value for our shareholders.”


“To sustain this trajectory, we have entered into a long-term lease for a new production facility in Ohio (AI data centers). This strategically located hub will serve as a primary logistics center for the Northeast and New England corridors, enabling us to localize production for our district heating and cooling offerings and capture additional regional market share. The region’s favorable and flexible labor environment further enhances our operational agility.”


“Supporting our long-term growth strategy, we also finalized a new credit facility with J.P. Morgan Chase. This agreement represents a watershed moment for the Company. We have standardized our borrowing platform globally at significantly improved terms. This transition optimizes our cost of capital while providing the liquidity necessary to support the next phase of our global expansion,” Mr. Sagr continued.


“With record earnings as our foundation and a modernized capital structure as our fuel, we enter the remainder of 2026 with strong confidence in our ability to scale our global operations and drive meaningful shareholder returns,” Mr. Sagr concluded.


2025 Results


Net sales were $210.9 million for the fiscal year ended January 31, 2026, an increase of $52.5 million, or 33.1%, from $158.4 million in the prior year. The growth was primarily driven by higher sales volumes across our key markets in the Middle East, Canada, and the United States


Gross profit was $69.5 million, or 33% of net sales, compared to $53.2 million, or 34% of net sales, in the prior year. The $16.3 million was driven by higher sales volumes and consistent gross margins globally.


General and administrative expenses were $35.3 million, compared to $28.0 million in the prior year. The increase of $7.3 million was primarily related to higher compensation costs and professional fees, including approximately $1.0 million relating to Sarbanes-Oxley 404 compliance in connection with our transition from a non-accelerated filer to an accelerated filer. This also includes a one-time compensation charge of approximately $2.0 million related to the departure of the previous CEO.


Selling expenses were $4.7 million, compared to $4.9 million in the years ended January 31, 2026 and 2025, respectively. The decrease of $0.2 million was primarily driven by lower payroll expenses during the year.


Interest expense, net was $1.8 million and $1.9 million in the years ended January 31, 2026 and 2025, respectively. The decrease of $0.1 million was the result of an overall reduction in interest rates during the year.


The Company's worldwide effective tax rates ("ETR") were 24.9% and 29.1% in the years ended January 31, 2026 and 2025, respectively. The change in ETR was largely due to changes in the mix of income and loss in various tax jurisdictions and the domestic Global Intangible Low-Taxed Income ("GILTI") inclusion.


Net income attributable to common stock was $17.0 million, or $ 2.09 per diluted share, for the fiscal year ended January 31, 2026, compared to $9.0 million, or $ 1.12 per diluted share, in the prior year. The 89% increase was driven by the significant growth in sales volumes and operational efficiencies discussed above, partially offset by the one-time charges previously noted and amounts attributable to non-controlling interest.


Perma-Pipe International Holdings, Inc.


Perma-Pipe International Holdings, Inc. (the “Company”) is a global leader in pre-insulated piping and leak detection systems for oil and gas gathering, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, the Company has operations at thirteen locations in seven countries.


Forward-Looking Statements


Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) fluctuations in the price of oil and natural gas and its impact on customer order volume for the Company's products; (ii) the Company’s ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (iii) decreases in government spending on projects using the Company’s products, and challenges to the Company’s non-government customers’ liquidity and access to capital funds; (iv) the Company’s ability to repay its debt and renew expiring international credit facilities; (v) the Company’s ability to effectively execute its strategic plan and achieve sustained profitability and positive cash flows; (vi) the Company's ability to collect a long-term account receivable related to a project in the Middle East; (vii) the Company’s ability to interpret changes in tax regulations and legislation; (viii) the Company's ability to use its net operating loss carryforwards; (ix) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company’s "over-time" revenue recognition; (x) the Company’s failure to establish and maintain effective internal control over financial reporting; (xi) the timing of order receipt, execution, delivery and acceptance for the Company’s products; (xii) the Company’s ability to successfully negotiate progress-billing arrangements for its large contracts; (xiii) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xiv) the Company’s ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xv) reductions or cancellations of orders included in the Company’s backlog; (xvi) risks and uncertainties specific to the Company's international business operations; (xvii) the Company’s ability to attract and retain senior management and key personnel; (xviii) the Company’s ability to achieve the expected benefits of its growth initiatives; (xix) the impact of pandemics and other public health crises on the Company and its operations; and (xx) the impact of cybersecurity threats on the Company’s information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at https://www.sec.gov and under the Investor Center section of our website (http://investors.permapipe.com.)


The Company's fiscal year ends on January 31. Years, results, and balances described as 2025, 2024, and 2023 are for the fiscal year ending January 31, 2026, 2025, and 2024, respectively.


Additional information regarding the Company's financial results for the fiscal year ended January 31, 2026, including management's discussion and analysis of the Company's financial condition and results of operations, is contained in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2026, which will be filed with the Securities and Exchange Commission on or about the date hereof and will be accessible at www.sec.gov and www.permapipe.com. For more information, visit the Company's website.


PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


(In thousands, except per share data)


(Unaudited)


 

 


 


Three Months Ended January 31,


 


 


Year Ended January 31,


 


 


 


2026


 


 


2025


 


 


2026


 


 


2025


 


Net sales


 


$


55,129


 


 


$


44,987


 


 


$


210,925


 


 


$


158,384


 


Gross profit


 


 


17,337


 


 


 


15,171


 


 


 


69,488


 


 


 


53,248


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Total operating expenses


 


 


10,367


 


 


 


9,732


 


 


 


40,039


 


 


 


32,947


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Income from operations


 


 


6,970


 


 


 


5,439


 


 


 


29,449


 


 


 


20,301


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Interest expense, net


 


 


505


 


 


 


451


 


 


 


1,822


 


 


 


1,940


 


Other (expense) income, net


 


 


(58


)


 


 


262


 


 


 


(134


)


 


 


107


 


Income before income taxes


 


 


6,407


 


 


 


5,250


 


 


 


27,493


 


 


 


18,468


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Income tax expense


 


 


787


 


 


 


1,685


 


 


 


6,844


 


 


 


5,377


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Net income


 


$


5,620


 


 


$


3,565


 


 


$


20,649


 


 


$


13,091


 


Less: Net income attributable to non-controlling interest


 


 


702


 


 


 


1,805


 


 


 


3,614


 


 


 


4,108


 


Net income attributable to common stock


 


$


4,918


 


 


$


1,760


 


 


$


17,035


 


 


$


8,983


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Weighted average common shares outstanding


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Basic


 


 


8,103


 


 


 


7,983


 


 


 


8,047


 


 


 


7,956


 


Diluted


 


 


8,206


 


 


 


8,073


 


 


 


8,148


 


 


 


8,015


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Earnings per share


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


Basic


 


$


0.61


 


 


$


0.22


 


 


$


2.12


 


 


$


1.13


 


Diluted


 


$


0.60


 


 


$


0.22


 


 


$


2.09


 


 


$


1.12


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


   

Note: Earnings per share calculations could be impacted by rounding.


PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES


CONDENSED CONSOLIDATED BALANCE SHEETS


(In thousands)


(Unaudited)


 

 


 


January 31,


 


 


 


2026


 


 


2025


 


ASSETS


 


 


 


 


 


 


 


 


Current assets


 


$


146,734


 


 


$


108,802


 


Long-term assets


 


 


70,752


 


 


 


56,439


 


Total assets


 


$


217,486


 


 


$


165,241


 


LIABILITIES AND STOCKHOLDERS' EQUITY


 


 


 


 


 


 


 


 


Current liabilities


 


$


79,789


 


 


$


54,063


 


Long-term liabilities


 


 


31,396


 


 


 


28,073


 


Total liabilities


 


 


111,185


 


 


 


82,136


 


Non-controlling interests


 


 


15,663


 


 


 


10,967


 


Stockholders' equity


 


 


90,638


 


 


 


72,138


 


Total liabilities and stockholders' equity


 


$


217,486


 


 


$


165,241


 


PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURE

ADJUSTED INCOME BEFORE TAX

(In thousands)

(Unaudited)


The following information contains a reconciliation of the non-GAAP financial measure of adjusted income before income tax and income before tax prepared in accordance with generally accepted accounting principles ("GAAP") for the three and twelve months ended January 31, 2026, and 2025, respectively. This reconciliation is intended to provide investors with useful information in evaluating the Company's performance. Adjusted income before tax includes certain adjustments as identified below. This measure is not considered an alternative to income before tax or other financial measures of performance that are prepared in accordance with GAAP. The Company believes that the exclusion of certain items from income before tax allows investors to more effectively evaluate the Company's operating performance and identify trends that might not be apparent due to the variability and infrequent nature of these items. In addition, the Company believes this measure provides meaningful information to investors when comparing results between periods and performance with respect to the Company's peers.


Adjustments were made for certain items as follows: (i) a one-time charge associated with the acceleration of executive compensation; (ii) a one-time litigation settlement charge; and (iii) other non-recurring items. These non-GAAP measures are provided to enhance the user's overall understanding of the company’s current financial performance and may not be comparable to similarly titled measures used by other companies.


The following table provides a reconciliation of the GAAP and non-GAAP financial measures:


 


 


For the three months ended


 


 


For the twelve months ended


 


 


 


January 31,


2026


 


 


January 31,


2025


 


 


January 31,


2026


 


 


January 31,


2025


 


Income before income tax (GAAP as reported)


 


$


6,407


 


 


$


5,250


 


 


$


27,493


 


 


$


18,468


 


Acceleration of certain executive compensation


 


 


-


 


 


 


-


 


 


 


2,018


 


 


 


-


 


Litigation settlement


 


 


-


 


 


 


-


 


 


 


-


 


 


 


35


 


Other one-time charges


 


 


-


 


 


 


-


 


 


 


88


 


 


 


517


 


Adjusted income before tax


 


$


6,407


 


 


$


5,250


 


 


$


29,599


 


 


$


19,020


 


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260416587944/en/



Permalink

https://www.aetoswire.com/en/news/54513390


Contacts

 

Perma-Pipe International Holdings, Inc.

Saleh Sagr

President, CEO, and Director


Perma-Pipe Investor Relations

281.941.2445

investor@permapipe.com

Amazfit Unveils the Cheetah 2 Pro, a Performance Running Watch Built for Marathon Preparation


 MILPITAS, Calif. - 

Titanium design meets structural lightness, engineered for the demands of marathon training cycles


(BUSINESS WIRE) -- Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Cheetah 2 Pro, the newest addition to its performance-focused Cheetah lineup. Built for marathon runners who believe preparation is everything, the Cheetah 2 Pro is designed around a simple belief: marathon performance is shaped by the work runners do throughout the training week. It brings structured running, strength-supportive training, and recovery insights into one focused preparation system, helping runners stay consistent through long marathon build-ups. Launching ahead of the Boston and London Marathons, the Cheetah 2 Pro is built to meet the demands of high-mileage training and race day alike.


Introducing Amazfit’s philosophy of refined performance and structural lightness, the Cheetah 2 Pro is engineered for runners who know speed is not only about miles and splits, but also the strength, recovery, and discipline that support performance over time. Rooted in a hybrid training philosophy, it helps runners build endurance alongside strength and recovery, supporting the durability and consistency needed for long marathon build-ups.


“Marathon training is about consistency, discipline, and being intentional with every part of your preparation. As I train for Boston, the Cheetah 2 Pro helps me stay locked in on the details that matter, from pacing to recovery, and it does it in a way that feels light, comfortable, and built for the demands of high-mileage training.”

Rory Linkletter, professional marathon runner and Amazfit athlete ambassador


Refined Performance, Engineered Without Excess


Speed should come from intelligent architecture, not added mass. Through structural lightness, unnecessary material is reduced while rigidity and precision are maintained, creating a marathon training watch that feels precise without feeling heavy. The Cheetah 2 Pro delivers advanced running performance in a streamlined design that feels fast, comfortable, and unobtrusive from daily training to race day.


Built for the demands of long training blocks and race day, the Cheetah 2 Pro pairs a Grade 5 titanium bottom case and middle frame with scratch-resistant sapphire glass to deliver durable, lightweight confidence without unnecessary bulk. A bright 1.32-inch AMOLED display keeps data clear and readable through early starts, shifting daylight, and late miles.


Training Designed for the Long Build


The Cheetah 2 Pro supports runners at every level with built-in running workouts focused on the foundations that matter most over distance. Aerobic base work builds endurance, threshold sessions improve efficiency, and strength-focused training supports durability so runners can handle higher mileage with greater resilience.


With Zepp Coach, runners receive intelligent, personalized training plans tailored to distances ranging from 3K to full marathon, adapting based on performance and progress. For those seeking deeper control, the watch also integrates with advanced third-party platforms such as TrainingPeaks, Runna, Strava and Intervals.icu.


Metrics for Smarter Running and Recovery


The Cheetah 2 Pro turns training data into clearer decisions, helping runners understand when to push, when to recover, and how to stay consistent through demanding training blocks. Advanced running metrics including pacing, lactate threshold, running power, gait tracking, and finish time predictions help runners better understand how they move, measure progress over time, and train with greater intention.


Within the Zepp app, recovery insights such as heart rate, HRV, sleep, and fatigue provide a more complete picture of how the body is responding to training load. Metrics including VO2 max, fatigue level, and training status help runners make smarter decisions about when to push forward and when to prioritize recovery, supporting consistency across long training cycles.


The Most Advanced GPS in the Cheetah Lineup


Featuring advanced dual-band GPS with multi-satellite positioning, the Cheetah 2 Pro delivers precise pacing and reliable route tracking, even when routes become more complex or focus begins to fade over long distances. Whether navigating city streets or winding courses, runners can rely on accurate location data to stay on pace and on course.


Endurance That Matches the Distance


Training does not stop because the battery does. The Cheetah 2 Pro offers up to 29 hours of GPS battery life, supporting marathon cutoff times around the world and extended efforts that require reliable performance from start to finish. For everyday use, the watch also delivers up to 17 days of battery life, ensuring it keeps pace with both training cycles and daily life.


The built-in dual-mode flashlight adds confidence during early morning and late evening runs, with adjustable brightness settings designed to improve visibility during outdoor workouts.


Pricing and Availability


The Cheetah 2 Pro will be available for purchase starting April 16, 2026, for $449.99 on Amazfit.com and select retailers.


About Amazfit


Amazfit, a global smart wearable and fitness leader, is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.


Amazfit builds smart wearables designed around movement — training with intention, recovery with balance, and evolution over time. Built for the way people train today, Amazfit blends endurance, strength, and recovery into a single, coherent rhythm to support sustainable progress over time.


Behind Amazfit is Zepp, which builds the intelligence that supports its training experience. For more information, visit www.amazfit.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260416320584/en/



Permalink

https://aetoswire.com/en/news/1604202654370


Contacts

Media Contacts

Max Borges Agency for Amazfit

amazfit@maxborgesagency.com


Mary Thompson Woodbury

Head of PR, Amazfit North America

Mary.woodbury@zepp.com

Experian Named a 2026 CIO 100 Award Winner

 Foundry’s CIO 100 Awards recognize organizations that demonstrate excellence and innovation in information technology


(BUSINESS WIRE) -- Experian has been named a 2026 CIO 100 Award winner by Foundry’s CIO for its enterprise workplace transformation, which integrates artificial intelligence and modern digital tools to improve productivity and decision-making across its global workforce.


For more than 40 years, the CIO 100 Awards have honored companies that drive business value through technology leadership.


“The organizations we’re recognizing this year are not simply maintaining operations, they are actively shaping business outcomes,” said Richard Smith, head of event content for the CIO 100 Awards and Conference. “Artificial intelligence, data, security and cloud capabilities now converge under a single leadership vision. This year’s winners reflect what is possible when those elements are fully aligned.”


Powering an AI-Enabled Workforce


A central component of the initiative is Experian’s focus on trusted, well-governed data, reinforced by strong guardrails to ensure AI and analytics deliver secure, reliable insights. Experian uses AI responsibly, with human oversight where appropriate, and takes no shortcuts when it comes to governance, privacy and security. The company has expanded its use of enterprise-grade AI tools, enabling employees to automate tasks and work more efficiently.


“Receiving the CIO 100 Award highlights how Experian is bringing together artificial intelligence, a modern digital workplace and trusted data to drive innovation across our global workforce,” said Alex Lintner, CEO of Technology and Software Solutions at Experian. “By equipping employees with these capabilities, we’re improving productivity, accelerating decisions and delivering better outcomes for our customers while advancing as a data- and AI-driven organization. This progress reflects the strong execution of our digital workplace team in delivering a modern, AI-enabled employee experience.”


From Transformation to Tangible Results


Led by the digital workplace team, the transformation is delivering measurable results across the organization. More than 17,000 employees now use AI-powered tools, generating over one million interactions each month. Onboarding readiness exceeds 90%, while employee satisfaction scores average 4.5 or higher. First-call resolution rates have improved to approximately 85%.


These gains are supported by a global operating model and are expected to deliver significant cost savings over three years. The initiative builds on Experian’s broader technology strategy, including a cloud-first transformation with Amazon Web Services (AWS) that has improved scalability and accelerated AI innovation.


Scaling Innovation Across a Global Enterprise


Experian also continues to expand its AI capabilities through the Experian Ascend Platform™, which supports customer decisioning with machine learning and real-time data insights. The platform is used by more than 1,400 users globally, processing millions of credit reports daily and billions of transactions each year. In addition to the evolution of EVA, Experian Virtual Assistant™ that expands personalized, conversational financial guidance to millions of consumers.


Experian executives and others from winning organizations were recognized at the CIO 100 Awards and Conference.


About Experian


Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain insights into the automotive market using our data, analytics and software. We also assist millions of people in achieving their financial goals and help them save time and money.


We operate across financial services, healthcare, automotive, agrifinance, insurance, and other industries.


A FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have 25,200 people across 33 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.


Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260416872002/en/



Permalink

https://www.aetoswire.com/en/news/1604202654380


Contacts

Michael Troncale

Experian Public Relations

+1 714 830 5462

michael.troncale@experian.com


 

Chaired by HRH Crown Prince, PIF Board of Directors Approves PIF 2026-2030 Strategy

 Next phase of PIF strategy sets out roadmap to 2030, as PIF continues to drive the economic transformation of Saudi Arabia

Strategy focuses on maximizing financial returns, strengthening investment efficiency and increasing private sector participation

Investments will be structured into three portfolios: Vision Portfolio, Strategic Portfolio and Financial Portfolio

Vision Portfolio will catalyze development of six ecosystems within the local economy

 


(BUSINESS WIRE)--The Board of Directors of PIF, chaired by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince, Prime Minister and Chairman of the Board of Directors of PIF, has approved PIF’s 2026-2030 strategy, which is a continuation of PIF’s long-term strategy. The strategy will focus on delivering competitive domestic ecosystems to connect sectors, unlock the full potential of strategic assets, maximize long-term returns, and continue to drive the economic transformation of Saudi Arabia and further enhance the quality of life of its citizens.


The 2026-2030 strategy marks a natural evolution as PIF moves from a period of rapid growth and acceleration to a new phase of sustained value creation, with a strengthened focus on maximizing impact, raising the efficiency of investments, and applying the highest standards of governance, transparency and institutional excellence. In addition, PIF will further enable the role of the private sector as an effective partner for sustainable economic development.


Under the 2026-2030 strategy, PIF has structured its investments into three portfolios. The Vision Portfolio aims to leverage synergies across strategic sectors, maximize value for PIF portfolio companies, and continue to drive the growth of the local economy. It will contribute to national priorities through the delivery of six competitive domestic ecosystems and by further integrating PIF’s investments. The Vision Portfolio will unlock new opportunities for the domestic private sector as an investor, partner and supplier, to further enable its role as an effective partner for sustainable economic development, while also attracting global partners and investors.


The six ecosystems include: Tourism, Travel & Entertainment; Urban Development & Livability; Advanced Manufacturing & Innovation; Industrials & Logistics; Clean Energy, Water & Renewables Infrastructure; and NEOM.


The Strategic Portfolio will actively manage key strategic assets to maximize financial returns and the economic impact of PIF’s companies, while supporting their efforts to attract capital and become global champions. Through the Strategic Portfolio, PIF will also continue to invest in opportunities arising from long-term global trends.


The Financial Portfolio will focus on delivering sustainable financial returns to further strengthen PIF’s financial position and continue to grow national wealth for future generations. It will manage PIF’s direct and indirect investments in global markets to maximize returns, while building a more diversified and resilient portfolio. It will further strengthen strategic international partnerships to help attract capital and increase access to global investment opportunities.


His Excellency Yasir Al-Rumayyan, Governor of PIF, said: “PIF’s strategy continues to deliver results as we grow domestically and internationally. In less than a decade, we have launched unprecedented projects, including giga-projects and major real estate developments, in addition to unique investments in strategic sectors such as artificial intelligence, gaming and esports, and renewable energy. PIF also grew assets under management six-fold and attracted global partners and capital to take part in Saudi Arabia’s transformation. PIF will continue to support Saudi Vision 2030 objectives by delivering competitive domestic ecosystems, investing in national champions that have the potential to scale globally, and forming global economic partnerships, building on what has been achieved under PIF’s 2021-2025 strategy.


“The 2026-2030 strategy is a natural next step in PIF’s growth journey. It offers our partners more opportunities to invest in high-quality assets and ecosystems, alongside PIF. In the next five years, we will continue to build on our great achievements and strengthen our global leadership to deliver success for PIF and Saudi Arabia.”


PIF will continue to invest with agility in both local and international markets and maintain its ability to respond to emerging opportunities that benefit the local economy and impact an ever-shifting global economy. It will maintain a disciplined focus on value realization, sustainable returns, enhanced capital efficiency and the highest institutional standards, as it drives innovation and advanced utilization of data and artificial intelligence.


PIF’s 2026-2030 strategy provides a clear strategic direction for the coming decades. It also strengthens PIF’s position as a local and global investor, with a diversified and resilient portfolio that contributes to Saudi Arabia’s long-term economic prosperity. PIF’s unique mandate will remain the same: to drive the economic transformation of Saudi Arabia and generate sustainable financial returns.


The strategy builds on the substantial progress and achievements delivered by PIF under its previous strategies, including:


Grown assets under management from $150 billion in 2015 to more than $900 billion

Achieved an annualized total shareholder return of over 7% since 2017

Invested more than $199 billion in new projects in Saudi Arabia from 2021 to 2025

Contributed more than $243 billion to real non-oil GDP from 2021 to 2024, equivalent to around 10% of Saudi Arabia’s total non-oil GDP in 2024

Spent together with its portfolio companies more than $157 billion with the local private sector from 2021 to 2024

Expanded PIF’s global presence in priority markets with subsidiary company offices in North America, Europe and Asia to deepen PIF’s ties in international markets and continue to invest in sectors, industries and companies shaping the future of the global economy

One of the few sovereign wealth funds with strong credit ratings from each of the world’s top three rating agencies. Moody’s rated PIF Aa3 with a stable outlook, while Fitch rated PIF A+, also with a stable outlook

This material is distributed by Teneo Strategy LLC on behalf of the PIF. Additional information is available at the Department of Justice, Washington, DC.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260415432832/en/



Permalink

https://aetoswire.com/en/news/1504202654354


Contacts

For media inquiries:

PIF Media Relations

Email: media@pif.gov.sa

Website: www.pif.gov.sa


 

Chemelex Makes Minority Investment in Algo8 to Advance AI-Driven Manufacturing

 (BUSINESS WIRE)--Chemelex, a global leader in electric thermal and sensing solutions, announced today that it has made a minority investment in Algo8, an industrial artificial intelligence (AI) company, to accelerate the use of AI in manufacturing.


The investment will support further development of Algo8’s technology while enabling Chemelex to enhance its manufacturing processes and improve productivity, while continuing to deliver high product quality to customers.


Chemelex Chief Executive Officer David Prystash will join Algo8’s Board of Advisors.


The partnership is built on existing commercial engagement and underscores Chemelex’s focus on applying advanced technologies to strengthen operational performance and supply reliability across its global manufacturing footprint.


Algo8 develops Plantbrain, a proprietary AI software that integrates data across industrial systems to generate predictive and prescriptive insights, helping manufacturers optimize operations, reduce downtime, and improve decision-making.


Chemelex deploys Algo8’s technology across its operations to improve process consistency, increase manufacturing efficiency, enable faster, data-driven decision-making and enhance supply reliability for customers.


For Algo8, the investment provides capital to accelerate product development and access to Chemelex’s global manufacturing base, supporting broader deployment of its platform in industrial environments.


“Investing in advanced technologies is central to how we continue to lead in manufacturing excellence,” said David Prystash, CEO of Chemelex. “Algo8’s approach to industrial AI aligns with our commitment to delivering high-quality, reliable products. Integrating these capabilities into our operations will enhance productivity, improve consistency, and strengthen our ability to meet customer demand.”


Nandan Mishra, CEO and Co-Founder of Algo8, said: “Partnering with Chemelex allows us to accelerate development of our platform and scale its deployment across global manufacturing environments. Together, we aim to deliver measurable performance improvements through AI-driven solutions.”


About Chemelex


Chemelex is a global leader in electric thermal and sensing solutions, protecting the world’s critical processes, places and people. With over 50 years of innovation and a commitment to excellence, we develop solutions that ensure safety, reliability, and efficiency in diverse environments – from industrial plants and data centers to people’s homes.


Chemelex trusted brands include Raychem, Tracer, Pyrotenax, and Nuheat, all enabling the world to move forward with confidence.


For more information, visit www.chemelex.com.


About Algo8


Algo8 is an industrial AI company developing software platforms for manufacturing and industrial environments. Its technology integrates data across systems to deliver predictive and prescriptive insights that improve efficiency, productivity, and operational performance.


The company operates across North America, Europe, the Middle East, and Asia.


For more information, visit www.algo8.ai.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260416344462/en/



Permalink

https://aetoswire.com/en/news/1604202654377


Contacts

Media Contact

Chemelex

Lowie Van Rymenant

VP Marketing

Lowie.vanrymenant@chemelex.com

+32 (478) 278 893